Page 1 | Search Results | Blood | American Society of Hematology

Skip to Main Content

Skip Nav Destination

1-3 of 3

Sort by

Sort Order Select

Journal Articles

EP31670, a dual-BET + p300 inhibitor, demonstrates pre-clinical efficacy, including in combination with JAK inhibition, in the hMPLW515L adoptive transfer model of myelofibrosis (MF)

Linda Fabris, Warren Fiskus, Kavi O'Connor, Zachary Zaroogian, Shishir Waghray, Gautam Borthakur, Prithviraj Bose, Naveen Pemmaraju, Lucia Masarova, Taghi Manshouri, Kapil Bhalla, Claes Wahlestedt, Ross Levine, Andrew Dunbar

Blood (2025) 146 (Supplement 1): 3759.

https://doi.org/10.1182/blood-2025-3759

Published: 2025

Journal Articles

AJ1-11095, a potent and highly selective type-II JAK2 inhibitor, shows enhanced therapeutic efficacy as compared with type-I JAK2 inhibitor ruxolitinib in models of myeloproliferative neoplasms (MPNs)

Marc Usart, Shivam Rai, Kavi O'Connor, Quentin Kimmerlin, Zachary Zaroogian, Matthew Wereski, Charlie Xu, Craig Masse, Stevan Hubbard, Ross Levine, Maria Kleppe, Radek Skoda, Andrew Dunbar

Blood (2025) 146 (Supplement 1): 1983.

https://doi.org/10.1182/blood-2025-1983

Published: 2025

Journal Articles

CXCL8/CXCR2 signaling mediates bone marrow fibrosis and is a therapeutic target in myelofibrosis

Blood (2023) 141 (20): 2508–2519.

https://doi.org/10.1182/blood.2022015418

Published: 2023

Includes: Supplemental data